SEC Company Response from Corvus Pharmaceuticals, Inc. (CRVS) (CIK 0001626971) (CRVS) — Mar 17, 2020
Corvus Pharmaceuticals, Inc. (CRVS) (CIK 0001626971)
Date: March 17, 2020 · CIK: 0001626971 · Accession: 0001104659-20-034837
AI Filing Summary & Sentiment
File numbers found in text: 333-237040
Letter
Corvus Pharmaceuticals, Inc.
863 Mitten Road, Suite 102
Burlingame, California 94010
March 17, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Courtney Lindsay
Re: Corvus Pharmaceuticals, Inc.
Registration Statement on Form S-3 (Registration No. 333-237040)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Corvus Pharmaceuticals, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on March 19, 2020, or as soon as practicable thereafter.
Thank you for your assistance in this matter.
Very truly yours,
Corvus Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Corvus Pharmaceuticals, Inc. 863 Mitten Road, Suite 102 Burlingame, California 94010 March 17, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Courtney Lindsay Re: Corvus Pharmaceuticals, Inc. Registration Statement on Form S-3 (Registration No. 333-237040) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Corvus Pharmaceuticals, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on March 19, 2020, or as soon as practicable thereafter. Thank you for your assistance in this matter. Very truly yours, Corvus Pharmaceuticals, Inc. By: /s/ Leiv Lea Leiv Lea Chief Financial Officer CC: Richard A. Miller, Corvus Pharmaceuticals, Inc. Alan C. Mendelson, Latham & Watkins LLP Miles P. Jennings, Latham & Watkins LLP